Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Ecallantide (Kalbitor) vs Icatibant (Firazyr)
An educational, source-based comparison of Ecallantide (Kalbitor) and Icatibant (Firazyr) — how each peptide works, what it's researched for, and what to know before going deeper.
Plasma kallikrein inhibitor for hereditary angioedema.
60-amino-acid recombinant protein that selectively inhibits plasma kallikrein, reducing bradykinin generation during HAE attacks.
- Hereditary angioedema (acute attacks, ≥12 yrs)
- • FDA-approved.
- • Boxed warning: anaphylaxis — administer by healthcare professional.
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
- Hereditary angioedema (acute attacks)
- • FDA-approved.
- • Injection-site reactions very common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Ecallantide (Kalbitor) | EDEMA trials | NEJM | 2010 | Improved HAE attack resolution vs placebo. |
| Icatibant (Firazyr) | FAST-3 trial | Annals of Allergy | 2011 | Faster symptom relief vs placebo in HAE attacks. |
Side-effect & safety grid
- FDA-approved.
- Boxed warning: anaphylaxis — administer by healthcare professional.
- FDA-approved.
- Injection-site reactions very common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Ecallantide (Kalbitor) vs Icatibant (Firazyr) — Key differences
- Class: Ecallantide (Kalbitor) is classified as Kallikrein Inhibitor · Immunology, while Icatibant (Firazyr) is Bradykinin Antagonist · Immunology.
- Primary research focus: Ecallantide (Kalbitor) — hereditary angioedema (acute attacks, ≥12 yrs); Icatibant (Firazyr) — hereditary angioedema (acute attacks).
- Tag: FDA-Approved · Rare Disease vs FDA-Approved · Rare Disease.